Clinical Trial Update: Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Resected NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating adding bevacizumab and erlotinib to carboplatin and docetaxel versus chemotherapy alone in resected non-small cell lung cancer; results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• CARBOPLATIN (Carboplatin)
• DOCETAXEL (DOCETAXEL)
• ERLOTINIB (Erlotinib)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2015-05-14